Dual agonists, like Survodutide and Tirzepatide, target two metabolic pathways simultaneously, offering potentially greater efficacy in treating conditions like MASH compared to single-target GLP-1 agonists, which focus on just one pathway
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment
Reduced appetite for ultra-processed and high-fat foods: Multiple studies show GLP-1 users report decreased cravings for sweets, fried foods, and alcohol a phenomenon researchers call the food noise reduction effect
Enhanced Metabolism: These injections ensure your body burns calories efficiently by boosting your metabolic rate
We must stress that melanotan 2 studies are lacking and this merits further research
Dosage: Never exceed the intended dose to avoid side effects